The need for new therapeutic agents: What is in the pipeline?

Clinical Microbiology and Infection, Supplement

Volumn 11, Issue 3, 2005, Pages 36-42

  Shah, P M ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Daptomycin; Gram positive; Methicillin resistant Staphylococcus aureus; Vancomycin resistant

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BAY 736944; BAY 737388; BETA LACTAM DERIVATIVE; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CIPROFLOXACIN; CLOXACILLIN; COTRIMOXAZOLE; DA 7867; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DK 507K; DW 286A; FLUCLOXACILLIN; GARENOXACIN; GATIFLOXACIN; GLYCOPEPTIDE; ICLAPRIM; LEVOFLOXACIN; LINEZOLID; MBX 037; MBX 500; METICILLIN; MOXIFLOXACIN; N [1 TERT BUTYL 2 OXO 2 [4 (2 THIAZOLYLMETHYL) 1 PIPERAZINYL]ETHYL] 3 CYCLOPENTYL 2 (N FORMYL N HYDROXYAMINOMETHYL)PROPIONAMIDE; NAFCILLIN; ORITAVANCIN; OXACILLIN; OXAZOLIDINEDIONE DERIVATIVE; PDF 386; PDF 713; PENICILLIN DERIVATIVE; PTK 0796; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMOPLANIN; RANBEZOLID; RIFAMPICIN; RO 482622; RO 655788; RU 75411; SITAFLOXACIN; TEICOPLANIN; TELITHROMYCIN; TETRACYCLINE; TIGECYCLINE; TRIMETHOPRIM; UNCLASSIFIED DRUG; VANCOMYCIN; VRC 4307; VRC 4887;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT FAILURE; REVIEW;

ENTEROCOCCUS FAECIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA;

ANTI-INFECTIVE AGENTS; DAPTOMYCIN; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; VANCOMYCIN RESISTANCE;

EID: 21744455460     PISSN: 14709465     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01141.x     Document Type: Article

References (29)

1. Menichetti F. Current and emerging serious Gram-positive infections. Clin Microbiol Infect 2005; 11 (suppl 3): 22-28.
2. Segreti J. Efficacy of current agents and consequences of resistance. Clin Microbiol Infect 2005; 11 (suppl 3): 29-35.
3. Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002; 62: 425-441.
4. Leclercq R. Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin. J Antimicrob Chemother 2001; 48 (suppl T1): 9-23.
5. Auckland C, Teare L, Cooke F et al. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J Antimicrob Chemother 2002; 50: 743-746.
6. Potoski BA, Mangino JE, Goff DA. Clinical failures of linezolid and implications for the clinical microbiology laboratory. Emerg Infect Dis 2002; 8: 1519-1520.
7. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-208.
8. Wilson P, Andrews JA, Charlesworth R et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2003; 51: 186-188.
9. Milatovic D, Verhoef J, Fluit AC. In vitro activity of iclaprim (AR-100) against Gram-positive and Gram-negative bacteria [abstract E-2006]. In: Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA: American Society for Microbiology, 2003; 213.
10. Chang S, Sievert DM, Hageman JC et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348: 1342-1347.
11. Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey medical center. J Antimicrob Chemother 2003; 52: 864-868.
12. CDC. Brief report: vancomycin-resistant Staphylococcus aureus - New York, 2004. MMWR 2004; 53: 322-323.
13. National Committee for Clinical Laboratory Standards (NCCLS). Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Information Supplement. M100-S12. Wayne, PA: NCCLS, 2002.
14. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarisation in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 2538-2544.
15. Akins RL, Rybak MJ. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother 2000; 44: 1925-1929.
16. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004; 53: 530-532.
17. Bush LM, Boscia JA, Wendeler M, Pitsakis PG, Kaye D. In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 1989; 33: 1198-1200.
18. 2+ and albumin on these drugs. Antimicrob Agents Chemother 1991; 35: 1710-1716.
19. Silverman JA, Oliver N, Andrew T, Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001; 45: 1799-1802.
20. Woodworth JR, Nyhart EH, Brier GL, Wolny JD, Black HR. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992; 36: 318-325.
21. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48: 63-68.
22. Dvorchik B. Moderate liver impairment has no influence on daptomycin pharmacokinetics. J Clin Pharmacol 2004; 44: 715-722.
23. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-1681.
24. Dini C, Berchtold H, Colladant C et al. Fluorinated riburamycins as potent MraY inhibitors: synthesis and in vitro biological evaluation [abstract F-359]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA: American Society for Microbiology, 2002; 180.
25. Tarantino PM, Zhi C, Wright GE, Brown NC. Inhibitors of DNA polymerase III as novel antimicrobial agents against Gram-positive eubacteria. Antimicrob Agents Chemother 1999; 43: 1982-1987.
26. Otani T, Tanaka M, Ito E, Kurosaka Y, Murakami Y, Onodera K et al. In vitro and in vivo antibacterial activities of DK-507K, a novel fluoroquinolone. Antimicrob Agents Chemother 2003; 47: 3750-3759.
27. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44: 1062-1066.
28. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47: 1318-1323.
29. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004; 48: 4665-4672.